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Plasma copeptin in preterm infants: a highly sensitive marker of
fetal and neonatal stress
Abstract
Context: Copeptin is a stable by-product of arginine-vasopressin synthesis and reflects its secretion by
the pituitary. Objective: The objective of the study was to investigate perinatal factors affecting copeptin
concentrations in preterm infants at birth and at 3 d of life. Design and Setting: This was a prospective
cross-sectional study at two Swiss university hospitals. Patients: One hundred sixty-seven preterm
infants were enrolled, 59 infants born between 24 and 31 wk gestational age, 50 infants between 32 and
34 wk, and 58 between 35 and 36 wk. Main Outcome Measure: Plasma copeptin concentrations,
determined by a CT-proAVP-luminescence-immunoassay, were measured. Results: Copeptin at birth
was significantly higher in preterm infants born vaginally [median (range) 366 (1-2900) pmol/liter, n =
43] than those born by cesarean section [6.9 (2-1580), n = 124]. In infants born after cesarean without
prior labor (n = 66), estimated fetal weight less than the fifth percentile, suspect fetal heart rate,
compromised placental perfusion, and chorioamnionitis were each associated with significantly elevated
cord copeptin. Copeptin at 3 d of life was not associated with cord blood copeptin but inversely related
to gestational age (Rs = -0.6, P < 0.001) and birth weight (Rs -0.612, P < 0.001). Day 3 copeptin
increased alongside the level of mechanical respiratory support. Conclusion: Copeptin is a highly
sensitive marker of perinatal stress.
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Disclosure Summary: NGM and UH are employed by BRAHMS Biomarkers, the manufacturer of the 1 
copeptin assay for which it owns patent rights (BRAHMS CT-proAVP LIA, BRAHMS Biomarkers, 2 
part of Thermo Fisher Scientific, Hennigsdorf/Berlin, Germany). The company had neither impact on 3 
design of the study nor on writing of the manuscript. The remaining authors have nothing to declare. 4 
Précis: Plasma copeptin in preterm infants both at birth and the first days of life is a sensitive marker 5 
of perinatal stress. 6 
Abbreviations: 7 
AVP   Arginine-vasopressin 8 
CT-proAVP   C-terminal portion of the AVP precursor 9 
GA  Gestational age 10 
LIA   Luminescence-immunoassay 11 
SGA  Small for gestational age 12 
CTG  Cardiotocogramm, fetal heart rate tracing 13 
14 
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Abstract 1 
CONTEXT: Copeptin is a stable by-product of arginine-vasopressin synthesis and reflects its secretion 2 
by the pituitary.  3 
OBJECTIVE: To investigate perinatal factors affecting copeptin concentrations in preterm infants at 4 
birth and at 3 days of life.  5 
DESIGN and SETTING: Prospective cross-sectional study at two Swiss university hospitals. 6 
PATIENTS: 167 preterm infants were enrolled, 59 infants born between 24 and 31 weeks gestational 7 
age, 50 infants between 32 and 34 weeks, and 58 between 35 and 36 weeks.   8 
MAIN OUTCOME MEASURE: Plasma copeptin concentrations, determined by a CT-proAVP-9 
Luminescence-immunoassay.  10 
RESULTS:  Copeptin at birth was significantly higher in preterm infants born vaginally (median 11 
[range] 366 [1-2900] pmol/L, n=43) than those born by caesarean section (6.9 [2-1580], n=126). In 12 
infants born after caesarean without prior labour (n=66), estimated fetal weight < 5th percentile, 13 
suspect fetal heart rate, compromised placental perfusion, and chorioamnionitis were each associated 14 
with significantly elevated cord copeptin. Copeptin at 3 days of life was not associated with cord 15 
blood copeptin but inversely related to gestational age (Rs -0.6, p<0.001) and birth weight (Rs -0.612, 16 
p<0.001). Day 3 copeptin increased alongside the level of mechanical respiratory support. 17 
CONCLUSION:  Copeptin is a highly sensitive marker of perinatal stress. 18 
19 
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Introduction 1 
Copeptin is a stable by-product of arginine-vasopressin (AVP) synthesis, it mirrors AVP release and 2 
can be determined reliably and quantitatively in plasma (1). Recent investigations of plasma copeptin 3 
concentrations in healthy and ill adults as well as in healthy newborn infants may be summarized as 4 
follows. First, in response to increased osmolality and deydration, plasma copeptin concentrations 5 
(normal < 5 pmol/L) (2) rise up to 5-fold (3). Second, increased copeptin concentrations (5-100-fold) 6 
are observed in response to physical stress, ischemia, and sepsis (4)(5)(6). Third, in newborn infants, 7 
the demands of spontaneous vaginal delivery results in a 100 to 1000-fold increase in copeptin 8 
concentrations in umbilical cord blood as compared to primary caesarean section (7). There is an 9 
emerging role for copeptin as a diagnostic and prognostic tool in patients with stroke and myocardial 10 
infarction (8)(9)(10)(11). In the present study, we investigated the impact of various perinatal factors 11 
on copeptin concentrations at birth and during the first days of life in preterm infants.  12 
 13 
Subjects and methods 14 
A total of 167 preterm infants born at the university hospitals of Basel and Zürich between March 15 
2009 and July 2010 were enrolled in this prospective cross-sectional study after obtaining written 16 
consent from the parents. This study was approved by the institutional review boards in Basel and 17 
Zurich. Infants were considered eligible for enrolment if birth occurred before completion of 37 18 
weeks’ gestational age (GA). GA was determined by the best estimate from a combination of the first 19 
day of mother’s last menstrual period and an early ultrasound scan in the first trimester. Infants were 20 
grouped by GA at birth, less than 32 (group 1, n=59), 32-34 (group 2, n = 50), 35-36 (group 3, n=58) 21 
completed weeks’ GA. Venous blood samples were drawn from the umbilical cord at the time of 22 
delivery and at 3 days of life.    23 
Clinical data were recorded as described previously (12), based on standardized definitions of the 24 
Swiss Neonatal Network. Small for gestational age (SGA) was defined as estimated fetal weight 25 
below the 5th percentile in the last ultrasound examination before birth. Fetal heart rate tracings 26 
(cardiotocogramm, CTG) were classified as suspect or normal by the obstetrician in charge according 27 
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to the FIGO [International Federation of Gynecology and Obstetrics] guidelines (13). 1 
Placentae (n=135) were histologically examined for signs of chorioamnionitis and of altered placental 2 
perfusion capacity. For complete patient characteristics see supplement 1. 3 
Venous blood was collected in EDTA tubes from the umbilical cord and at 3 days of life. Samples 4 
were handled as described previously (7). Measurements were done in a single batch with a sandwich 5 
immunoluminometric assay (BRAHMS CT-proAVP LIA, BRAHMS Biomarkers, part of Thermo 6 
Fisher Scientific Hennigsdorf, Germany) as described before (7).  7 
Continuous variables are given as median (M) [range]. Statistical analyses were made using PASW 8 
18.0 (SPSS inc., Chicago, Ill.) with strictly non-parametric tests (Spearman’s rank order correlation, 9 
Mann-Whitney U test,  Kruskal-Wallis, or Fisher’s exact test). A p-value < 0.05 was considered as 10 
significant. 11 
 12 
Results  13 
Copeptin at birth: Vaginal delivery (n=43) had the strongest impact on copeptin concentrations at 14 
birth irrespective of GA or birth weight (Fig. 1A). Accordingly, there was a correlation between 15 
copeptin at birth and umbilical artery pH (Rs 0.354, p<0.001). Infants who went on to develop 16 
intraventricular hemorrhage had significantly elevated cord blood copeptin concentrations (median 17 
[range] 166 [4-1600] pmol/L, n=10) compared to controls (12 [1-2900] pmol/L, n=81, p=0.013).  18 
To address more specifically the impact of other perinatal factors on copeptin independent the 19 
demand caused by vaginal parturition, we analyzed infants born by caesarean section (n=124). 20 
Copeptin concentrations were higher when the following variables were present as compared to 21 
absent: SGA present 11 [2-815] pmol/L, n=32, absent 5.7 [2-815] pmol/L, n=63, p=0.006; suspect 22 
fetal heart rate immediately before birth present 25 [5-1580] pmol/L, n=26, absent 4.9 [2-409] pmol/L, 23 
n=69, p<0.001; compromised placental perfusion present 11 [2-1580] pmol/L, n=46, absent 4.9 [2-24 
565] pmol/L, n=49, p=0.005; early onset sepsis proved by positive blood culture drawn immediately 25 
after birth 138 [22-815] pmol/L, n=4, absent 6.45 [2-1580] pmol/L, n=105, p=0.008. Maternal 26 
leukocyte counts correlated weakly with copeptin at birth (Rs 0.229, p=0.019). 27 
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Finally, we excluded from analysis also all secondary caesarean sections and focused exclusively on 1 
those without prior labour, defined as primary caesarean sections, n=66.  SGA, suspect fetal heart rate, 2 
chorioamnionitis, and compromised placental perfusion were each associated with significantly higher 3 
copeptin concentrations, even more pronounced as compared to the analysis of all caesareans (Figure 4 
2). Umbilical artery acidosis but not umbilical artery base excess was related to some of these 5 
characteristics (Figure 2). In addition, maternal leukocyte counts correlated significantly with copeptin 6 
at birth (Rs 0.413, p=0.002), and copeptin concentrations were higher in infants receiving empirical 7 
antibiotics immediately after birth (median [range] 24 [4-263] pmol/l, n=7, vs 5.7 [2-565] pmol/L, 8 
n=51, p=0.029).  9 
Copeptin at day 3: Copeptin concentrations determined at 3 days of life were significantly higher in 10 
very preterm infants (group 1) as compared to less preterm infants of group 2 or 3, irrespective of the 11 
mode of delivery (Fig. 1B) and consequently correlated inversely with GA (Rs -0.6, p<0.001) and 12 
birth weight (Rs -0.612, p<0.001).  13 
The presence of each of the following parameters was significantly (all p<0.001) associated with 14 
higher copeptin concentrations (pmol/L) at day 3: Respiratory support (spontaneous intermittend 15 
mechanical ventilation: 35 [19-199] pmol/L, n=19; nasal continuous positive airway pressure: 26 [1-16 
199] pmol/L, n=46, no pressure support: 18 [2-55] pmol/L, n=31); empirical administration of 17 
antibiotics immediately after birth 24 [1-199] pmol/l, n=29, vs no antibiotics 18 [2-70] pmol/L, n=78, 18 
p=0.025); early onset sepsis proved by positive blood culture drawn immediately after birth 42 [12-64] 19 
pmol/L, n=5, absent 19 [1-199] pmol/L, n=102; patent ductus arteriosus (hemodynamic relevant and 20 
treated: 38 [8-199] pmol/L, n=12; patent but not relevant, no treatment; 27 [7-66] pmol/L, 21 
n=13;closed: 18 [1-64] pmol/L, n=82, p =0.001).  22 
Day 3 copeptin concentrations were not related to maximal postnatal weight loss but to same-day 23 
serum sodium concentrations (Rs 0.442, p<0.001). No correlation was seen between copeptin levels at 24 
birth and at day 3, neither when studying all infants nor when studying subgroups. 25 
 26 
27 
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Discussion 1 
The data presented here demonstrate that preterm infants release huge amounts of copeptin into the 2 
systemic circulation during vaginal delivery. The magnitude is similar to that previously reported for 3 
term infants (7). Histo-anatomical findings have indeed demonstrated AVP stores piling up in the 4 
pituitary until 28 weeks GA (14). The cumulated AVP/copeptin is apparently secreted in response to 5 
events during vaginal birth. When we analyzed infants born by caesarean section without prior labour, 6 
signs and symptoms of impaired placental function and infection were associated with increased cord 7 
blood copeptin. Thus, cord blood copeptin is a highly sensitive albeit little specific marker of 8 
fetal/neonatal distress.  We found no correlation between venous copeptin concentrations at birth and 9 
at 3 days of life. Day 3 copeptin was not related to mode of delivery but increased with decreasing 10 
gestational age and birth weight, as well as level of respiratory support.   11 
 12 
13 
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Figure legends: 1 
Figure 1: Copeptin concentrations in venous cord blood at birth (Fig. 1A) and in venous blood at 2 
3 days of life (Fig. 1B) with respect to weeks’ gestational age and mode of delivery.    3 
Weeks’ gestational age (GA) at birth is grouped in less than 32 (group 1, n=59), 32-34 (group 2, 4 
n=50), 35-36 completed weeks GA (group 3, n=58). Copeptin concentrations are presented as box 5 
(interquartile range) and whisker (5-95 % range) plots. Grey coloured boxes represent data obtained 6 
after vaginal delivery, white boxes after abdominal delivery (caesarean section). Level of significance 7 
between various groups as indicated: *, p<0.05; **, p<0.01; ***, p<0.001; n.s., not significant. 8 
 9 
Figure 2: Copeptin concentrations in venous cord blood at birth (Fig. 2A) and pH values in 10 
paired arterial cord blood samples at birth (Fig. 2B) obtained after primary caesarean section 11 
according to various causes of fetal stress.    12 
Data are presented as box (interquartile range) and whisker (5-95 % range) plots. Data are grouped 13 
according small for gestation age (SGA; present, grey boxes; no SGA, white boxes), cardiotocogramm 14 
(CTG; pathologic, pathol., grey boxes; normal, white boxes), perfusion of placenta (perfusion pl.; 15 
reduced, grey boxes; normal, white boxes), and chorioamnionitis (chorioamn.; present, grey boxes; no, 16 
white boxes). Level of significance: *, p<0.05; **, p<0.01; ***, p<0.001; n.s., not significant. 17 
18 
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